<table width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Rifabutin Interaction Studies<footnote>ND - No data<br/> AUC - Area under the Concentration vs. Time Curve<br/> Cmax - Maximum serum concentration</footnote>
</caption>
<col align="left" valign="top" width="20%"></col>
<col align="left" valign="top" width="20%"></col>
<col align="left" valign="top" width="20%"></col>
<col align="left" valign="top" width="40%"></col>
<thead>
<tr>
<th stylecode="Lrule Rrule">Coadministered Drugs</th>
<th stylecode="Rrule">Effect on Rifabutin</th>
<th stylecode="Rrule">Effect on Coadministered Drug</th>
<th stylecode="Rrule">Comments</th>
</tr>
</thead>
<tbody>
<tr stylecode="Botrule">
<td colspan="4" stylecode="Lrule Rrule">ANTIVIRALS</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Amprenavir </td>
<td stylecode="Rrule">2.9-fold ↑ AUC, 2.2-fold ↑ Cmax</td>
<td stylecode="Rrule">No significant change in kinetics.</td>
<td stylecode="Rrule">A 50% reduction in the rifabutin dose is recommended when combined with amprenavir. Increased monitoring for adverse reactions is warranted. </td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Delavirdine </td>
<td stylecode="Rrule">ND</td>
<td stylecode="Rrule">Oral clearance ↑ 5-fold resulting in significantly lower mean trough plasma concentrations (18±15 to 1.0±0.7 µM)</td>
<td stylecode="Rrule">Study conducted in HIV-1 infected patients  Rifabutin is not recommended for patients dosed with delavirdine mesylate 400 mg q8h.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Didanosine </td>
<td stylecode="Rrule">No significant change in kinetics.</td>
<td stylecode="Rrule">No significant change in kinetics at steady state.</td>
<td stylecode="Rrule"></td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Fosamprenavir/ritonavir </td>
<td stylecode="Rrule">64% ↑ AUC <footnote id="ft2"> - Drug plus active metabolite</footnote>
</td>
<td stylecode="Rrule">35% ↑ AUC and 36% ↑ Cmax, no effect Ctrough (amprenavir)</td>
<td stylecode="Rrule">Dosage reduction of rifabutin by at least 75% (to 150 mg every other day or three times per week) is recommended when combined with fosamprenavir</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Indinavir </td>
<td stylecode="Rrule">204% ↑ in AUC</td>
<td stylecode="Rrule">32%↓ in AUC</td>
<td stylecode="Rrule"></td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Lopinavir/ritonavir</td>
<td stylecode="Rrule">5.7-fold ↑ AUC, 3.4 fold ↑ Cmax<footnoteref idref="ft2"></footnoteref>
</td>
<td stylecode="Rrule">No significant change in lopinavir kinetics.</td>
<td stylecode="Rrule">Dosage reduction of rifabutin by at least 75% of the usual dose of 300 mg/day is recommended (i.e., a maximum dose of 150 mg every other day or three times per week). Increased monitoring for adverse reactions is warranted. Further dosage reduction of rifabutin may be necessary. </td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Saquinavir </td>
<td stylecode="Rrule">ND</td>
<td stylecode="Rrule">40% ↓ in AUC</td>
<td stylecode="Rrule"></td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Ritonavir </td>
<td stylecode="Rrule">4 fold increase in AUC, 2.5 fold increase in Cmax</td>
<td stylecode="Rrule">ND</td>
<td stylecode="Rrule">In the presence of ritonavir the subsequent risk of side effects, including uveitis may be increased   . If a protease inhibitor is required in a patient treated with rifabutin, agents other than ritonavir should be considered.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Tipranavir/ritonavir[133]</td>
<td stylecode="Rrule">2.9-fold ↑ AUC, 1.7-fold ↑ Cmax</td>
<td stylecode="Rrule">No significant change in tipranavir kinetics.</td>
<td stylecode="Rrule">Therapeutic drug monitoring of rifabutin is recommended. </td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Zidovudine </td>
<td stylecode="Rrule">No significant change in kinetics.</td>
<td stylecode="Rrule">Approximately 32%↓ in Cmax and AUC</td>
<td stylecode="Rrule">A large controlled clinical study has shown that these changes are of no clinical relevance.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="4" stylecode="Lrule Rrule">
<content stylecode="bold">ANTIFUNGALS</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">ANTIFUNGALS</td>
<td stylecode="Rrule">82% ↑ in AUC</td>
<td stylecode="Rrule">No significant change in steady-state plasma concentrations</td>
<td stylecode="Rrule"></td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Itraconazole </td>
<td stylecode="Rrule">ND</td>
<td stylecode="Rrule">70% to 75% ↓ in Cmax and AUC</td>
<td stylecode="Rrule">One case report suggests a kinetic interaction resulting in an increase in serum rifabutin levels and a risk for developing uveitis in the presence of itraconazole. </td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Posaconazole</td>
<td stylecode="Rrule">31%↑ Cmax, 72%↑ AUC</td>
<td stylecode="Rrule">43%↓ Cmax, 49%↓ AUC</td>
<td stylecode="Rrule">If the drugs are co-administered, patients should be monitored for adverse events associated with rifabutin administration. </td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Voriconazole</td>
<td stylecode="Rrule">195%↑ Cmax, 331%↑ AUC <footnote> - voriconazole dosed at 400 mg twice daily</footnote>
</td>
<td stylecode="Rrule">Rifabutin (300 mg once daily) decreased the Cmax and AUC of voriconazole at 200 mg twice daily by 69% and 78%, respectively. During co-administration with rifabutin, the Cmax and AUC of voriconazole at 350 mg twice daily were 96% and 68% of the levels when administered alone at 200 mg twice daily. At a voriconazole dose of 400 mg twice daily  Cmax and AUC were 104% and 87% higher, respectively, compared with voriconazole alone at 200 mg twice daily.</td>
<td stylecode="Rrule">If the benefit outweighs the risk, rifabutin may be coadministered with voriconazole if the maintenance dose of voriconazole is increased to 5 mg/kg intravenously every 12 hours or from 200 mg to 350 mg orally, every 12 hours (100 mg to 200 mg orally, every 12 hours in patients less than 40 kg). Careful monitoring of full blood counts and adverse events to rifabutin (e.g. uveitis) is recommended when rifabutin is coadministered with voriconazole</td>
</tr>
<tr stylecode="Botrule">
<td colspan="4" stylecode="Lrule Rrule">
<content stylecode="bold">ANTI-PCP (Pneumocystis carinii pneumonia)</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Dapsone</td>
<td stylecode="Rrule">ND</td>
<td stylecode="Rrule">Approximately 27% to 40% ↓ in AUC</td>
<td stylecode="Rrule">Study conducted in HIV infected patients (rapid and slow acetylators).</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Sulfamethoxazole-Trimethoprim</td>
<td stylecode="Rrule">No significant change in Cmax and AUC</td>
<td stylecode="Rrule">Approximately 15% to 20% ↓ in AUC</td>
<td stylecode="Rrule">In another study, only trimethoprim (not sulfamethoxazole)  had  14% ↓ in AUC and 6%↓ in Cmax but were not considered clinically significant.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="4" stylecode="Lrule Rrule">
<content stylecode="bold">ANTI-MAC (Mycobacterium avium intracellulare complex)</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Azithromycin </td>
<td stylecode="Rrule">No PK interaction </td>
<td stylecode="Rrule">No PK interaction </td>
<td stylecode="Rrule"></td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Clarithromycin</td>
<td stylecode="Rrule">Approximately 77% ↑ in AUC</td>
<td stylecode="Rrule">Approximately 50%↓ in AUC</td>
<td stylecode="Rrule">Study conducted in HIV infected patients. Dose of rifabutin should be adjusted in the presence of clarithromycin</td>
</tr>
<tr stylecode="Botrule">
<td colspan="4" stylecode="Lrule Rrule">
<content stylecode="bold">ANTI-TB (Tuberculosis)</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Ethambutol</td>
<td stylecode="Rrule">ND</td>
<td stylecode="Rrule">No significant change in AUC or Cmax</td>
<td stylecode="Rrule"></td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Isoniazid </td>
<td stylecode="Rrule">ND</td>
<td stylecode="Rrule">Pharmacokinetics not affected</td>
<td stylecode="Rrule"></td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Pyrazinamide</td>
<td stylecode="Rrule">ND</td>
<td stylecode="Rrule">ND</td>
<td stylecode="Rrule">Study data being evaluated.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="4" stylecode="Lrule Rrule">
<content stylecode="bold">OTHER</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Methadone </td>
<td stylecode="Rrule">ND</td>
<td stylecode="Rrule">No significant effect</td>
<td stylecode="Rrule">No apparent effect of rifabutin on either peak levels of methadone or systemic exposure based upon AUC. Rifabutin kinetics not evaluated.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Ethinylestradiol</td>
<td stylecode="Rrule">ND</td>
<td stylecode="Rrule">35%↓ AUC<br/>20%↓ Cmax</td>
<td stylecode="Rrule">Patients should be advised to use other methods of contraception.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Norethindrone</td>
<td stylecode="Rrule">ND</td>
<td stylecode="Rrule">46%↓ AUC</td>
<td stylecode="Rrule">Patients should be advised to use other methods of contraception.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Tacrolimus </td>
<td stylecode="Rrule">ND</td>
<td stylecode="Rrule">ND</td>
<td stylecode="Rrule">Authors report that rifabutin decreases tacrolimus  trough blood levels.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Theophylline </td>
<td stylecode="Rrule">ND</td>
<td stylecode="Rrule">No significant change in AUC or Cmax compared with baseline.</td>
<td stylecode="Rrule"></td>
</tr>
</tbody>
</table>